BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 31156623)

  • 1. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
    de Aguiar RB; de Moraes JZ
    Front Immunol; 2019; 10():1023. PubMed ID: 31156623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of Bevacizumab With Cancer Immunotherapy.
    Chen DS; Hurwitz H
    Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
    Bourhis M; Palle J; Galy-Fauroux I; Terme M
    Front Immunol; 2021; 12():616837. PubMed ID: 33854498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
    Collins TS; Hurwitz HI
    Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR; Tsimberidou AM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
    Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
    Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
    Lee WS; Yang H; Chon HJ; Kim C
    Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
    Mueller T; Freystein J; Lucas H; Schmoll HJ
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
    Jászai J; Schmidt MHH
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.
    Wahl O; Oswald M; Tretzel L; Herres E; Arend J; Efferth T
    Curr Med Chem; 2011; 18(21):3136-55. PubMed ID: 21671856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.